Phase 3 N=392 Efficacy and Safety of SPARC0921 in Subjects With Spasticity
Spasticity
Primary: Treatment Failure Rate — 36.1; 43.2 percentage of subjects — p=0.2062
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=184 Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children
Infections, Meningococcal
Primary: Percentage of Participants With rSBA-Antibody Titers Greater Than or Equal to (>=) 1:8 For Each of the 4 Serogroups at 24 Months After Booster Vaccination — 98.4; 23.8…
Phase 3 N=1,135 Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome Characterized by Constipation
Primary: Number of Overall Responders - ITT Population — 54; 81; 91 Participants
Phase 3 N=138 Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Influenza A Virus Infection
Primary: Clinical Status at Day 7 — 2; 2; 15; 10 Participants — p=0.54
Phase 3 N=1,054 The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
Irritable Bowel Syndrome Characterized by Constipation
Primary: Number of Overall Responders - ITT Population — 63; 106; 103 Participants
Phase 3 N=118 Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands
Scabies · Head Lice
Primary: Number of Participants With Headlice — 3 Participants
Phase 3 N=1,656 Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Primary: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL — 1.19; 1.03; 1.24 Exacerbations per year — p=0.6490
Phase 3 N=403 A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Small Cell Lung Carcinoma
Primary: Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 in the Global Population — 4.3; 5.2 Months — p=0.0170
Phase 3 N=831 Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis
Tinea Pedis
Primary: Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Equivalence: Per-Protocol Population) — 89; 90…
Phase 3 N=403 Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
Bipolar I Disorder
Primary: Change From Baseline in the YMRS Total Score at Week 16 — -15.2 Units on a scale
Phase 3 N=108 A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
Postpartum Depression
Primary: Change From Baseline at 60 Hours in 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score — -12.12; -14.62 score on a scale — p=0.0160
Phase 3 N=211 A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.
Liver Transplant
Primary: Percentages of Participants Showing Clinical Benefit by Renal Function Stratification — 4.76; 3.77; 14.29; 16.04 Percentages of partcipants — p=0.9423
Phase 3 N=138 A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
Postpartum Depression
Primary: Change From Baseline at 60 Hours in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score — -14.04; -19.54; -17.72 score on a scale — p=0.0013
Phase 3 N=514 Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period — -1.02; -0.38 percentage of HbA1c — p=<0.0001
Phase 3 N=457 Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
Psoriatic Arthritis
Primary: Proportion of Subject Who Reached (American College of Rheumatology Score of 20) ACR20 — 71.3; 73.9; 73.2; 73.6 percentage of participants